Physician profile
Martin E Avalos
NPI 1033101985
$3,034.38
in general payments reported to CMS, 2019-2025
25 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $301 · 2021: $588 · 2022: $405 · 2023: $496 · 2024: $608 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,364.03 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,500.71 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $167.04 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.17 | 2019-2024 | Xifaxan |
| Pfizer INC. | $148.07 | 2019-2025 | |
| Madrigal Pharmaceuticals | $136.06 | 2024 | Rezdiffra |
| Intuitive Surgical, INC. | $103.23 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $96.15 | 2022-2024 | Dupixent |
| Allergan, INC. | $93.81 | 2019 | |
| Celgene Corporation | $65.10 | 2022-2023 | Zeposia |
| Vivus LLC | $56.18 | 2021-2024 | Pancreaze |
| Genzyme Corporation | $55.90 | 2023 | |
| Braintree Laboratories, INC. | $55.61 | 2019-2022 | |
| Fujifilm Healthcare Americas Corporation | $52.86 | 2024 | Fujifilm |
| Mallinckrodt Hospital Products INC. | $47.09 | 2024 | Terlivaz |
| Redhill Biopharma INC. | $44.41 | 2020-2023 | Talicia, Movantik, Aemcolo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $43.48 | 2019 | |
| Axonics, INC. | $42.86 | 2021-2024 | Axonics |
| Intercept Pharmaceuticals, INC. | $39.29 | 2021-2022 | |
| Exact Sciences Corporation | $32.28 | 2025 | The Cologuard Plus Collection Kit |
| Mauna Kea Technologies, INC. | $24.67 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $19.41 | 2024 | Bylvay |
| Aimmune Therapeutics, INC. | $16.10 | 2024 | |
| Lilly USA, LLC | $14.45 | 2024 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $14.20 | 2021 | |
| Medtronic, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Avalos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.